Purchase this article with an account.
Stuart J. McGimpsey, Jayne V. Woodside, Louise Bamford, Sarah E. C. M. Gilchrist, Ryan Graydon, Gareth C. McKeeman, Ian S. Young, Anne E. Hughes, Chris C. Patterson, Dermot O’Reilly, David McGibbon, Usha Chakravarthy; Retinal Vein Occlusion, Homocysteine, and Methylene Tetrahydrofolate Reductase Genotype. Invest. Ophthalmol. Vis. Sci. 2005;46(12):4712-4716. doi: 10.1167/iovs.04-1229.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
purpose. The aim of this case–control study was to investigate the relationship between homocysteine (tHcy), 5,10 methylene tetrahydrofolate reductase (MTHFR) C677T genotype, folate and vitamin B12 status, and retinal vein occlusion (RVO).
methods. Subjects with RVO (n = 106) were recruited from outpatient and inpatient sources. Controls (n = 98) were selected to achieve a similar age and sex distribution. Full ocular examination was performed and medical history was taken for each study participant. Plasma and serum samples were analyzed for tHcy level and folate and vitamin B12 status, and extracted DNA was assessed for the MTHFR C677T genotype.
results. There was no significant difference in plasma tHcy level or thermolabile MTHFR allele frequency between subjects and controls. Similarly, there was no significant difference in folate or vitamin B12 status between subjects and controls. MTHFR genotype did not affect folate or vitamin B12 concentrations in subjects or controls. However, tHcy was significantly higher in thermolabile homozygotes than in nonthermolabile homozygotes (ratio of geometric means, 1.35; 95% confidence interval [CI], 1.04–1.74; P = 0.024).
conclusions. Hyperhomocysteinemia, the MTHFR C677T mutation, and folate and vitamin B12 status are not important risk factors for RVO in this population.
This PDF is available to Subscribers Only